MedTrace Logo

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

NCT00306553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

CYT004-MelQbG10

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Principal Investigators

  • Alexander Knuth, MD · Dept. of Oncology, Univerity Hospital Zuerich, CH

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306553 on ClinicalTrials.gov